TUDCA CoQ10 Creatine Combination Therapy Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative disorders and autoimmune diseases are inadequate, as existing medications often require increased doses, causing side effects, and there are no disease-modifying drugs available to prevent these conditions, which are linked by shared pathophysiological mechanisms involving inflammation and neuronal dysfunction.
Innovation Solution
A combination of tauroursodeoxycholic acid (TUDCA) or ursodeoxycholic acid (UDCA), coenzyme Q10 (CoQ10) as ubiquinone or ubiquinol, and creatine is administered to target multiple pathways leading to neurodegeneration, providing a synergistic neuroprotective effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat neurodegenerative disorders, then some symptoms can be improved, but increased doses are required as the disease progresses causing side effects
Solution Approach 1:
The patent combines multiple compounds with different mechanisms of action (anti-inflammatory agents, antioxidants, mitochondrial function enhancers, protein aggregation inhibitors) into a single pharmaceutical composition. This multi-target approach addresses multiple pathophysiological pathways simultaneously, providing effective symptom relief and potential disease modification without requiring high doses of individual medications that cause side effects
2Reliability
If existing medications are used to treat neurodegenerative disorders, then some symptoms can be improved, but there are no disease-modifying drugs available to prevent these conditions
Solution Approach 1:
The pharmaceutical composition is designed to intervene in multiple early pathophysiological pathways including inflammation, oxidative stress, mitochondrial dysfunction, and protein aggregation. By addressing these upstream mechanisms before they cause irreversible neuronal damage, the composition aims to prevent or delay disease onset and progression, not merely treat symptoms after they appear
3Ease of manufacture
If a single medication is used to target one dysfunctional process, then that specific process can be addressed, but it is difficult to treat heterogeneous ND populations with diverse pathophysiological mechanisms
Solution Approach 1:
The patent creates a universal pharmaceutical composition that simultaneously targets multiple conserved pathophysiological pathways common across different neurodegenerative disorders and patient subgroups. The multi-component formulation includes agents that address inflammation, oxidative stress, mitochondrial dysfunction, and protein aggregation - mechanisms that are shared across Alzheimer's, Parkinson's, and other NDs, making the treatment broadly applicable to heterogeneous patient populations
Data Source
AI summary
A method of treating or preventing a neurodegenerative disorder or a peripheral autoimmune disorder is disclosed. The method comprises administering to a patient in need thereof a combination of (a) tauroursodeoxycholic acid (TUDCA) or ursodeoxycholic acid (UDCA), (b) coenzyme Q10 (CoQ10) as ubiquinone or ubiquinol, and (c) creatine. The combination is shown to have synergistic effects in reducing the inflammatory cytokines IL-6 and TNF-α. The combination also significantly increases NFH filament and tubulin filament areas suggesting improved neuronal growth. Unit dosage forms are disclosed. Dosages are disclosed.